{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:54:33Z","timestamp":1772164473310,"version":"3.50.1"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: The epidermal growth factor receptor (EGFR) is amplified and overexpressed in adult glioblastoma, with response to targeted inhibition dependent on the underlying biology of the disease. EGFR has thus far been considered to play a less important role in pediatric glioma, although extensive data are lacking. We have sought to clarify the role of EGFR in pediatric high-grade glioma (HGG).<\/jats:p>\n                  <jats:p>Experimental Design: We retrospectively studied a total of 90 archival pediatric HGG specimens for EGFR protein overexpression, gene amplification, and mutation and assessed the in vitro sensitivity of pediatric glioma cell line models to the small-molecule EGFR inhibitor erlotinib.<\/jats:p>\n                  <jats:p>Results: Amplification was detected in 11% of cases, with corresponding overexpression of the receptor. No kinase or extracellular domain mutations were observed; however, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two anaplastic oligodendrogliomas and a gliosarcoma overexpressing EGFRvIII in the absence of gene amplification and coexpressing platelet-derived growth factor receptor \u03b1. Pediatric glioblastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-type PTEN. Phosphorylated receptor tyrosine kinase profiling showed a specific activation of platelet-derived growth factor receptor \u03b1\/\u03b2 in EGFRvIII-transduced pediatric glioblastoma cells, and targeted coinhibition with erlotinib and imatinib leads to enhanced efficacy in this model.<\/jats:p>\n                  <jats:p>Conclusions: These data identify an elevated frequency of EGFR gene amplification and EGFRvIII mutation in pediatric HGG than previously recognized and show the likely necessity of targeting multiple genetic alterations in the tumors of these children. (Clin Cancer Res 2009;15(18):5753\u201361)<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-08-3210","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T21:55:31Z","timestamp":1252446931000},"page":"5753-5761","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines"],"prefix":"10.1158","volume":"15","author":[{"given":"Dorine A.","family":"Bax","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Suzanne E.","family":"Little","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Lynley","family":"Marshall","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Lara","family":"Perryman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Marie","family":"Regairaz","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Marta","family":"Viana-Pereira","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Raisa","family":"Vuononvirta","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Swee Y.","family":"Sharp","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Jo\u00e3o N.","family":"St\u00e1vale","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Safa","family":"Al-Sarraj","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Rui M.","family":"Reis","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Andrew D.J.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"},{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"David W.","family":"Ellison","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Paul","family":"Workman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Paediatric Oncology and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 3Paediatric Oncology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 4Pharamacology and New Treatments of Cancer, Institut de Canc\u00e9rologie, Gustave Roussy, Villejuif, France; 5Life and Health Science Research Institute, Universidade do Minho, Braga, Portugal; 6Breakthrough Breast Cancer, The Institute of Cancer Research; 7Neuropathology, Kings College Hospital, London, United Kingdom; 8Department of Pathology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; and 9Neuropathology, St Jude Children's Research Hospital, Memphis, Tennessee"}]}],"member":"1086","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"2022061022260817800_bib1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1042\/bj3240855","article-title":"Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)","volume":"324","author":"Chu","year":"1997","journal-title":"Biochem J"},{"key":"2022061022260817800_bib2","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1371\/journal.pmed.0030485","article-title":"Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain","volume":"3","author":"Lee","year":"2006","journal-title":"PLoS Med"},{"key":"2022061022260817800_bib3","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"2022061022260817800_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/carcin\/bgm058","article-title":"EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes","volume":"28","author":"Grandal","year":"2007","journal-title":"Carcinogenesis"},{"key":"2022061022260817800_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/carcin\/23.5.683","article-title":"Genetics and new approaches to cancer therapy","volume":"23","author":"Cavenee","year":"2002","journal-title":"Carcinogenesis"},{"key":"2022061022260817800_bib6","first-page":"1106","article-title":"Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model","volume":"63","author":"Ding","year":"2003","journal-title":"Cancer Res"},{"key":"2022061022260817800_bib7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/1078-0432.CCR-06-1453","article-title":"The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization","volume":"13","author":"Johns","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2004.07.004","article-title":"Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance","volume":"72","author":"Lammering","year":"2004","journal-title":"Radiother Oncol"},{"key":"2022061022260817800_bib9","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1073\/pnas.95.10.5724","article-title":"Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases","volume":"95","author":"Nagane","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061022260817800_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1074\/jbc.273.1.200","article-title":"Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor","volume":"273","author":"Moscatello","year":"1998","journal-title":"J Biol Chem"},{"key":"2022061022260817800_bib11","doi-asserted-by":"crossref","first-page":"46313","DOI":"10.1074\/jbc.M106571200","article-title":"The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor","volume":"276","author":"Klingler-Hoffmann","year":"2001","journal-title":"J Biol Chem"},{"key":"2022061022260817800_bib12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/00006123-199912000-00034","article-title":"Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens","volume":"45","author":"Feldkamp","year":"1999","journal-title":"Neurosurgery"},{"key":"2022061022260817800_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2006.01.003","article-title":"Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours","volume":"32","author":"Halatsch","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"2022061022260817800_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jnci\/dji161","article-title":"Epidermal growth factor receptor, protein kinase B\/Akt, and glioma response to erlotinib","volume":"97","author":"Haas-Kogan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2022061022260817800_bib15","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"key":"2022061022260817800_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/1078-0432.CCR-06-1992","article-title":"PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors","volume":"13","author":"Mellinghoff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib17","first-page":"3335","article-title":"Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion","volume":"62","author":"Lal","year":"2002","journal-title":"Cancer Res"},{"key":"2022061022260817800_bib18","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1158\/1078-0432.CCR-03-0521","article-title":"Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme","volume":"10","author":"Learn","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","volume":"9","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"2022061022260817800_bib20","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1078-0432.CCR-05-2510","article-title":"Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response","volume":"12","author":"Sarkaria","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib21","volume-title":"Pathology and genetics of tumors of the nervous system","author":"Kleihues","year":"2000"},{"key":"2022061022260817800_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1056\/NEJMoa012224","article-title":"Expression of p53 and prognosis in children with malignant gliomas","volume":"346","author":"Pollack","year":"2002","journal-title":"N Engl J Med"},{"key":"2022061022260817800_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1215\/15228517-2006-036","article-title":"Molecular pathogenesis of pediatric astrocytic tumors","volume":"9","author":"Nakamura","year":"2007","journal-title":"Neuro Oncol"},{"key":"2022061022260817800_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2006.06.8213","article-title":"Clinical and molecular characteristics of malignant transformation of low-grade glioma in children","volume":"25","author":"Broniscer","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022061022260817800_bib25","first-page":"3620","article-title":"ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma","volume":"9","author":"Gilbertson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib26","first-page":"1786","article-title":"Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood","volume":"5","author":"Bredel","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib27","first-page":"418","article-title":"Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort","volume":"105","author":"Pollack","year":"2006","journal-title":"J Neurosurg"},{"key":"2022061022260817800_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11060-007-9513-1","article-title":"Tyrosine kinase expression in pediatric high grade astrocytoma","volume":"87","author":"Liang","year":"2008","journal-title":"J Neurooncol"},{"key":"2022061022260817800_bib29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/modpathol.3800415","article-title":"Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood","volume":"18","author":"Korshunov","year":"2005","journal-title":"Mod Pathol"},{"key":"2022061022260817800_bib30","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1158\/1078-0432.CCR-07-0398","article-title":"Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney","volume":"13","author":"Little","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061022260817800_bib31","first-page":"913","article-title":"Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas","volume":"28","author":"Viana-Pereira","year":"2008","journal-title":"Anticancer Res"},{"key":"2022061022260817800_bib32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/1541-7786.MCR-06-0085","article-title":"Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas","volume":"4","author":"Puputti","year":"2006","journal-title":"Mol Cancer Res"},{"key":"2022061022260817800_bib33","doi-asserted-by":"crossref","first-page":"R1028","DOI":"10.1186\/bcr1341","article-title":"Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis","volume":"7","author":"Reis-Filho","year":"2005","journal-title":"Breast Cancer Res"},{"key":"2022061022260817800_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1006\/bbrc.1998.9646","article-title":"Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1\u03b1 promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins","volume":"252","author":"Hobbs","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061022260817800_bib35","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2022061022260817800_bib36","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.bmcl.2007.02.032","article-title":"Synthesis and biological evaluation of pyrido[3\u2032,2\u2032:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110\u03b1 inhibitors","volume":"17","author":"Hayakawa","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"2022061022260817800_bib37","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/0008-5472.CAN-06-4615","article-title":"Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases","volume":"67","author":"Raynaud","year":"2007","journal-title":"Cancer Res"},{"key":"2022061022260817800_bib38","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.4161\/cc.6.22.4922","article-title":"Uncovering therapeutic targets for glioblastoma: a systems biology approach","volume":"6","author":"Huang","year":"2007","journal-title":"Cell Cycle"},{"key":"2022061022260817800_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"2022061022260817800_bib40","first-page":"29","article-title":"Epidermal growth factor receptor expression in oligodendroglial tumors","volume":"149","author":"Reifenberger","year":"1996","journal-title":"Am J Pathol"},{"key":"2022061022260817800_bib41","doi-asserted-by":"crossref","first-page":"11172","DOI":"10.1158\/0008-5472.CAN-06-2438","article-title":"Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array","volume":"66","author":"Wong","year":"2006","journal-title":"Cancer Res"},{"key":"2022061022260817800_bib42","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2022061022260817800_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2990.2005.00660.x","article-title":"Genetic alteration and expression of the phosphoinositol-3-kinase\/Akt pathway genes PIK3CA and PIKE in human glioblastomas","volume":"31","author":"Knobbe","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2022061022260817800_bib44","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1038\/sj.onc.1210290","article-title":"PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion","volume":"26","author":"Liu","year":"2007","journal-title":"Oncogene"},{"key":"2022061022260817800_bib45","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1128\/MCB.00783-06","article-title":"Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry","volume":"26","author":"Kumar","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2022061022260817800_bib46","first-page":"187","article-title":"Gene aberrations in childhood brain tumors","volume":"46","author":"Kucerova","year":"2000","journal-title":"Folia Biol (Praha)"},{"key":"2022061022260817800_bib47","first-page":"445","article-title":"Drugging the cancer genome: new challenges of infrequent and combinatorial targets","volume":"8","author":"Workman","year":"2007","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/15\/18\/5753\/1984170\/5753.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/15\/18\/5753\/1984170\/5753.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:38:13Z","timestamp":1654907893000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/15\/18\/5753\/74406\/EGFRvIII-Deletion-Mutations-in-Pediatric-High"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":47,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2009,9,14]]},"published-print":{"date-parts":[[2009,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-3210","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22440010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6517390.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22440010.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6517390","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}